The<unk>  (CO-ADD) is a not-for-profit initiative created in 2015 reaching out to chemists in academia and research organisations who have compounds that were not designed as antibiotics and would not otherwise be screened for<unk>  activity. These academic compounds are screened against a key panel of<unk> -resistant bacterial strains -superbugs. Multi-drug resistant microbes are a serious health treat, and exploration of novel chemical diversity is essential to find new antibiotics. CO-ADD's goal is to find new, diverse compounds to combat the superbug crisis in screening chemical compounds for<unk>  activity against key ESKAPE pathogens, E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, S. aureus (MRSA), as well as the fungi C. neoformans and C. albicans. CO-ADD is supported by the Wellcome Trust through a Strategic Award and The University of Queensland (Institute for Molecular Bioscience), where the compound screening facilities are located.
Community for Open Antimicrobial Drug Discovery
Connecting Organizations for Regional Disease Surveillance
International Coalition of Medicines Regulatory Authorities
Discovery of disease-causing pathogens
Global Research Collaboration for Infectious Disease Preparedness
Glossary of clinical research
Good clinical laboratory practice
Scientific Advisory Group for Origins of Novel Pathogens